# Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

> **NCT02249182** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 226 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02249182
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-05
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-08-24
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249182, "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02249182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*